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ABSTRACT
Epidermal growth factor receptor (EGFR) mutants drive lung tumorigenesis and
are targeted for therapy. However, resistance to EGFR inhibitors has been observed,
in which the mutant EGFR remains active. Thus, it is important to uncover mediators
of EGFR mutant-driven lung tumors to develop new treatment strategies. The protein
tyrosine phosphatase (PTP) Shp2 mediates EGF signaling. Nevertheless, it is unclear
if Shp2 is activated by oncogenic EGFR mutants in lung carcinoma or if inhibiting the
Shp2 PTP activity can suppress EGFR mutant-induced lung adenocarcinoma. Here, we
generated transgenic mice containing a doxycycline (Dox)-inducible PTP-defective
Shp2 mutant (tetO-Shp2CSDA). Using the rat Clara cell secretory protein (CCSP)rtTA-directed transgene expression in the type II lung pneumocytes of transgenic
mice, we found that the Gab1-Shp2 pathway was activated by EGFRL858R in the lungs
of transgenic mice. Consistently, the Gab1-Shp2 pathway was activated in human
lung adenocarcinoma cells containing mutant EGFR. Importantly, Shp2CSDA inhibited
EGFRL858R-induced lung adenocarcinoma in transgenic animals. Analysis of lung tissues
showed that Shp2CSDA suppressed Gab1 tyrosine phosphorylation and Gab1-Shp2
association, suggesting that Shp2 modulates a positive feedback loop to regulate
its own activity. These results show that inhibition of the Shp2 PTP activity impairs
mutant EGFR signaling and suppresses EGFRL858R-driven lung adenocarcinoma.

INTRODUCTION

tyrosine-based activation motif (BTAM) consisting of
phosphorylated Tyr-627 and Tyr-659 [2]. Gab1-Shp2
binding activates the Shp2 PTP activity and mediates
activation of Erk1/2 and Src family kinases (SFKs) by
EGF [2-5]. Thus, in addition to EGFR, EGF paradoxically
activates a PTP to mediate the EGFR protein tyrosine
kinase (PTK) signaling.
Knockdown of Shp2 by shRNAs partially
inhibits proliferation of cancer cells in cell cultures [6].
Importantly, far greater effects of Shp2 knockdown have

Shp2 is a nonreceptor PTP encoded by the human
PTPN11 gene [1]. It has tandem SH2 domains in the
N-terminal region, a PTP domain, and a C-terminal region
containing tyrosine phosphorylation sites. Binding of Shp2
SH2 domains to specific tyrosine phosphorylated sites
relieves autoinhibition and activates Shp2. In epidermal
growth factor (EGF)-stimulated cells, Shp2 binds to
tyrosine-phosphorylated Gab1 at the bisphosphoryl
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been observed consistently in tumor xenograft growth
assays in vivo, suggesting that Shp2 plays a critical role
in tumor growth [6, 7]. Since Shp2 plays a positive role
in oncogenic signaling and tumorigenesis, it is a potential
target for development of novel anti-cancer drugs. In fact,
several efforts are underway to develop Shp2 inhibitors as
potential therapeutic agents [8-14].
EGFR is the second most frequently mutated
oncogene in lung adenocarcinoma after KRAS [15].
Significantly, Shp2 is a positive regulator of both EGFR
and Ras signaling. Moreover, gain-of-function (GOF)
Shp2 mutants are found in human lung carcinomas and
can induce lung tumors in mice [16, 17]. Approximately
80% of EGFR mutations in non-small cell lung cancer
(NSCLC) are either deletion of the conserved four
amino acids LREA residues in exon 19 or a L858R point
mutation in exon 21 [18]. Expression of these GOF EGFR
mutants in type II lung pneumocytes directed by a rat
Clara cell secretory protein (CCSP) promoter in CCSPrtTA/tetO-EGFR mutant bitransgenic mice induces lung
adenocarcinoma [19-21]. NSCLC harboring these GOF
EGFR PTK domain mutants are selectively sensitive to
the EGFR-selective PTK inhibitors (TKIs) erlotinib and
gefitinib. However, de novo and acquired drug resistance
mechanisms such as the gatekeeper T790M EGFR
mutation have been observed in lung cancer patients [18,
21, 22]. Therefore, it is necessary to develop new EGFR
PTK inhibitors and/or to target additional tumor promoting
molecules to improve lung cancer treatment [18, 21, 22].

Although EGF stimulates Shp2 activation, it is not
entirely clear whether Shp2 is active in lung epithelial
cells harboring GOF EGFR mutants and whether Shp2 is
important for mutant EGFR to drive lung adenocarcinoma.
In this study, we generated transgenic mice expressing
a PTP-defective (catalytic residues C459S/D425A
mutations), dominant-negative Shp2 mutant (tetOShp2CSDA) to assess the effects of Shp2 PTP inhibition
in a transgenic mouse model of mutant EGFR-driven lung
adenocarcinoma. Using NSCLC cell lines carrying GOF
EGFR mutants and transgenic mice expressing EGFRL858R,
we provide evidence that EGFR mutants activate Shp2
in human lung adenocarcinoma cells and in mouse lung
tissues. Furthermore, Shp2CSDA suppresses EGFRL858Rinduced lung adenocarcinoma in transgenic animals.

RESULTS
Shp2 signaling pathway is activated by mutant
EGFR in lung adenocarcinoma cells
EGFR activates Shp2 by phosphorylating Gab1,
which binds and activates Shp2 [2]. In HCC827 and
H1975 human lung adenocarcinoma cells that harbor
mutant EGFR (del19 and L858R/T790M mutations,
respectively), Gab1 was constitutively tyrosine
phosphorylated and bound Shp2 (Fig. 1). This indicates

Figure 1: Shp2-mediated Erk1/2 pathway is activated by mutant EGFR in lung adenocarcinoma cells. HCC827 (A) and

H1975 (B) cells were mock-treated or treated with EGFR PTK inhibitors erlotinib or WZ4002 as indicated. Cell lysates were analyzed
by immunoblotting with indicated antibodies or subjected to immunoprecipitation with anti-Gab1 antibody and immunoprecipitates were
analyzed by immunoblotting with antibodies to Shp2 or Gab1.
www.impactjournals.com/oncotarget

6192

Oncotarget

that Shp2 is constitutively activated in these lung
adenocarcinoma cells. Moreover, active Erk1/2 (pErk1/2)
was readily detectable in these cells (Fig. 1). To determine
whether Gab1 tyrosine phosphorylation and binding to
Shp2 are attributed to mutant EGFR in these cells, we
treated HCC827 and H1975 cells with the EGFR tyrosine
kinase inhibitor erlotinib or WZ4002. Erlotinib inhibited
EGFR and Gab1 tyrosine phosphorylation in HCC827
cells at the lowest concentration tested (0.25 µM). This
led to dissociation of Shp2 from Gab1 (Fig. 1A). H1975
cells are resistant to erlotinib due to the T790M gatekeeper
mutation [21]. Hence, erlotinib did not cause Gab1Shp2 dissociation in H1975 cells (Fig. 1B). WZ4002
was reported to inhibit the EGFR T790M mutant [23].
Treatment of H1975 cells with WZ4002 inhibited EGFR

and Gab1 tyrosine phosphorylation and resulted in Gab1Shp2 dissociation (Fig. 1B, right panels).
An established role of Shp2 in EGFR signaling is to
mediate Erk1/2 activation. As shown in Fig. 1, inhibition
of Gab1-Shp2 interaction by erlotinib in HCC827 and by
WZ4002 in H1975 cells correlated with inactivation of
Erk1/2. In comparison, erlotinib did not inhibit Erk1/2 in
H1975 cells. These data indicate that the Shp2 signaling
pathway is activated by the GOF EGFR mutants in these
lung adenocarcinoma cells.
To determine if Shp2 is involved in cell proliferation
of HCC827 and H1975 cells, we used siRNAs to knock
down Shp2 in these cells. Consistent with a role of Shp2
in mediating Erk1/2 activation, Shp2 knockdown reduced
pErk1/2 level in HCC827 and H1975 cells (Fig. 2A).

Figure 2: Effects of Shp2 inhibition on lung adenocarcinoma cells containing mutant EGFR. A, HCC827 and H1975 cells

were transfected with Shp2 siRNAs (siR), non-silencing control siRNA (NS), or mock-treated (P). Cell lysates were analyzed for Shp2
knockdown and active Erk1/2 by immunoblotting. B, Cells were plated in 96-well plates followed by transfection with Shp2 siRNAs or
control siRNA as above. The relative number of viable cells was measured 6 days post transfection and normalized to untransfected cells.
Data represent two (HCC827) and four (H1975) independent experiments performed in quintuple. *, p <0.05. C, HCC827 containing Doxinducible Shp2 shRNAs [6] were treated with Dox or left untreated, cell lysates were analyzed with indicated antibodies. D, HCC827 cells
were transfected with HA-Erk2 plus control vector (-), Gab1FF, or Shp2CSDA, and treated with EGF or left untreated. HA-Erk2 activation
were analyzed by immunoblotting of pErk2 after immunoprecipitation of the transfected HA-Erk2. E, HCC827 and H1975 cells were
treated with indicated concentrations of SPI-112Me in 96-well plates as described in Materials and Methods and viable cells were measured
on Day 6. Data were from three independent experiments performed in triplicates (n = 9) (graph). Right panel, cells were treated with SPI112Me overnight and cell lysates were analyzed by immunoblots with indicated antibodies.
www.impactjournals.com/oncotarget
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While the non-silencing (NS) siRNAs had no effect on
the pErk1/2 level or cell proliferation, Shp2 knockdown
inhibited proliferation of HCC827 and H1975 cells by
42% and 39%, respectively (Fig. 2A, B).
To further confirm that Shp2, Gab1-Shp2
interaction, and Shp2 PTP activity mediate Erk1/2
activation in lung adenocarcinoma cells that harbor
mutant EGFR, we compared the pErk1/2 level in isogenic
HCC827 cells containing two different Dox-inducible
Shp2 shRNAs (Fig. 2C). We also determined effects of
a Shp2-binding defective Gab1Y627F/Y659F mutant
(Gab1FF) and a Shp2 PTP-inactive mutant (Shp2CSDA)
on Erk1/2 activation in HCC827 cells (Fig. 2D). The
pErk1/2 level was markedly reduced in Dox-induced Shp2
knockdown in HCC827 (Fig. 2C). Expression of Gab1FF
or Shp2CSDA inhibited activation of co-transfected
Erk2 both in the absence or presence of EGF exposure
in HCC827 cells (Fig. 2D). These data demonstrate
that Gab1-Shp2 interaction and Shp2 PTP activity play
important roles in mediating Erk1/2 activation by the
mutant EGFR in HCC827 cells.
SPI-112Me is a cell permeable Shp2 inhibitor [11,
24]. To further evaluate the role of Shp2 PTP activity
in HCC827 and H1975 cells, we treated these cells
with various concentrations of SPI-112Me. SPI-112Me

inhibited pErk1/2 and proliferation of HCC827 and H1975
cells (Fig. 2E).

Generation of transgenic mice carrying a Doxinducible PTP-defective Shp2 mutant
GOF EGFR mutants induce lung tumors in
transgenic mouse models of lung adenocarcinoma [1921]. To determine if inhibition of Shp2 PTP activity can
suppress lung tumor development in a transgenic mouse
model of mutant EGFR, we generated transgenic mice
containing a Dox-inducible PTP-defective, dominantnegative Shp2 (Shp2CSDA). By design, controlled
expression of Shp2CSDA in the progenitor cells of lung
adenocarcinoma can be achieved by breeding the tetOShp2CSDA transgenic mice with CCSP-rtTA transgenic
mice [25] and feeding the CCSP-rtTA/tetO-Shp2CSDA
(C/Sdn) bitransgenic mice with Dox diet (Fig. 3B).
We obtained 41 pups from two separate
microinjection experiments. Among them, 9 founder lines
exhibited germline transmission of the tetO-Shp2CSDA
transgene. By RT-PCR analysis of mRNA expression
and immunoprecipitation-immunoblotting analysis of
protein expression, we identified transgenic mice that

Figure 3: Generation and characterization of transgenic mice. A, Diagrams of the tetO-Shp2CSDA, tetO-EGFRL858R [19] and

CCSP-rtTA [25] transgenes of mice used in this study. B, The breeding scheme for production of bitransgenic and tritransgenic mice. C,
Tissue samples from brain (Br), lung (Lu), liver (Li), spleen (Sp), kidney (Ki), small intestine (In), and colon (Co) of monotransgenic
tetO-Shp2CSDA Line-65 (S65) and Line-669 (S669) mice were analyzed by RT-PCR for the presence of Shp2CSDA mRNA. D, C/
Sdn bitransgenic mice from Line-65, Line-389, and Line-669 were fed with regular chow or Dox diet for 4 weeks. Lung tissue samples
were analyzed by RT-PCR to examine Shp2CSDA mRNA expression. E, C/S65/EL858R and C/S669/EL858R tritransgenic mice were
fed with regular rodent chow or Dox diet for 2 or 4 weeks. Lung tissue samples were analyzed by RT-PCR for mRNA expression or by
immunoprecipitation-immunoblotting analysis for the presence of Shp2CSDA protein.
www.impactjournals.com/oncotarget
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Shp2CSDA suppresses EGFRL858R-induced Erk1/2
and Src activation

either had detectable leaky (un-induced) expression of
the Shp2CSDA transgene or had no detectable leaky
expression (Fig. 3 and Supplementary Fig. 1). Some of
these transgenic lines were crossed with CCSP-rtTA mice
to generate C/Sdn bitransgenic mice and screened for
Dox-inducible expression of Shp2CSDA in the lung. After
initial characterization, we selected Line-65 and Line-669
for the subsequent study (Fig. 3). Line-65 had detectable
mRNA of the Shp2CSDA transgene in the absence of Dox
in the brain, lung, liver, spleen, kidney, small and large
intestine. Nevertheless, upon Dox induction, Shp2CSDA
expression was increased in the lung of these mice (Fig.
3E). Line-669, as well as Line-389, had no detectable
Shp2CSDA in the absence of Dox and showed Doxinduced expression of Shp2CSDA mRNA and protein
in the lung. Moreover, Dox-induced bi- or tritransgenic
mice containing Line-65 did not appear to have higher
Shp2CSDA protein in the lung tissues than those
containing Line-669.
Although Line-65 mice have a low level of
leaky expression of the Shp2CSDA mRNA, like other
Shp2CSDA transgenic mouse lines generated in our study,
we have not observed any abnormal growth or breeding
behavior. Histology of lungs from Dox-fed bitransgenic C/
Sdn mice was indistinguishable from that of the wildtype
mice (Supplementary Fig. 2).

To determine if the PTP-defective Shp2CSDA
inhibits Shp2-mediated EGFR signaling in the lungs
of transgenic mice, we produced CCSP-rtTA/tetOEGFRL858R (C/EL858R) bitransgenic mice and CCSPrtTA/tetO-Shp2CSDA/tetO-EGFRL858R (C/Sdn/EL858R)
tritransgenic mice. This was accomplished by crossing
C/Sdn bitransgenic mice with tetO-EGFRL858R mice (Fig.
3B). The resulting F1 offspring were then used in our
study. After induction with Dox for 2-8 weeks, lung tissues
from the transgenic mice were analyzed.
Immunoblot analysis using an EGFRL858R-specific
antibody confirmed Dox-induced expression of the
EGFRL858R mutant in C/EL858R bitransgenic mice and
C/Sdn/EL858R tritransgenic mice (Fig. 4). Compared
to wildtype control mice, pErk1/2 and pSrc(Y416)
levels were increased in the lungs of Dox-induced C/
EL858R bitransgenic mice, indicating that EGFRL858R
activated Erk1/2 and Src in the lungs of these mice. In
8 of 9 lung tissue samples that we have analyzed, the
pErk1/2 levels were decreased in the Dox-induced C/Sdn/
EL858R tritransgenic mice compared to the C/EL858R
bitransgenic mice (Fig. 4 and Supplementary Fig. 3).
Similarly, pSrc(Y416) levels were decreased in 5 of 5 lung
tissue samples from the Dox-induced tritransgenic mice
compared to the samples from the C/EL858R bitransgenic
mice. In contrast, no consistent effects on pAkt and pStat3
were observed in the Dox-induced tritransgenic mice (Fig.

Figure 4: EGFRL858R-activated signaling molecules in transgenic mice. Transgenic mice were fed with Dox diet for 2-8 weeks.

Lung tissues were flushed twice with 10 ml PBS and snap-frozen in liquid nitrogen. Frozen tissues were thawed and lysed with the lysis
buffer. Equal amount of proteins in Triton X-100 soluble supernatants were analyzed by immunoblotting with indicated antibodies. W,
wildtype, B, C/EL858R bitransgenic, T, C/S65/EL858R or C/S669/EL858R tritransgenic.
www.impactjournals.com/oncotarget
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4 and Supplementary Fig. 3). These results suggest that
Shp2CSDA inhibited EGFRL858R-induced Erk1/2 and Src
activation in the lungs of these tritransgenic mice.

Within 2 weeks of Dox induction, C/EL858R mice
developed focal atypical adenomatous hyperplasia (Fig.
5A). This progressed rapidly to extensive, diffused nonmucinous adenocarcinoma with lepidic pattern within
4 weeks after Dox-induction (Fig. 5A, second column).
Bronchioloalveolar adenoma appeared at week 6 and
progressed to more solid adenoma and adenocarcinoma
(> 0.5 mm in diameter) by week 8 (Fig. 5A). In
comparison, following parallel Dox induction, C/Sdn/
EL858R tritransgenic mice from both Line-65 and Line669 developed markedly fewer hyperproliferative lesions
compared to C/EL858R bitransgenic mice (Fig. 5A, B).

Shp2CSDA inhibits EGFRL858R-induced lung
tumors
To analyze the effects of Shp2CSDA on EGFRL858Rinduced lung tumors, C/EL858R and C/Sdn/EL858R mice
were induced with Dox for 2 to 8 weeks and lung tissues
were stained with H&E for histological examination.

Figure 5: Lung hyperproliferative lesions in transgenic mice. A, H&E sections of lungs from transgenic mice. Transgenic mice

were fed with Dox diet for 2-8 weeks. Lungs were collected and processed as described in Materials and Methods. H&E stained slides
were scanned with a ScanScope XT slide scanner (Aperio). Examples of H&E stained sections at each time point after Dox induction from
bitransgenic and two different tritransgenic lines are presented. Top panels from each transgenic line show images of whole lung sections.
The bottom panels from each transgenic line show a higher magnification (200x) of the boxed areas. B, Box-and-Whiskers plot of the
extent of hyperproliferative lesions in the lungs of Dox-induced transgenic mice. Three 4 µm sections that were 25 µm apart from each
lung paraffin block were stained with H&E. Images were acquired and analyzed using a histology pattern recognition algorithm (Aperio).
Areas of hyperproliferative lesions were calculated. Numbers on each column indicate the number of mice analyzed in that set of samples.
*, p <0.05. Hyperproliferative lesions include atypical adenomatous hyperplasia, non-mucinous adenocarcinoma with lepidic pattern,
bronchioloalveolar adenoma, and solid adenoma (<0.5 mm in diameter) and adenocarcinoma (>0.5 mm in diameter).
www.impactjournals.com/oncotarget
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To measure the diffuse lung hyperproliferative
lesions in these mouse lung tissues, we used the Aperio
Genie® histology pattern recognition program to semiquantitatively estimate areas of hyperproliferative lesions
as described in Materials and Methods (Supplementary
Fig. 4). Although the algorithm recognized the small
bronchiolar epithelia as lesions, this systematical error
did not affect our comparison of lung hyperproliferative
lesions because it generally affected <1% of the estimated
lesion areas and all lung H&E slides were measured using
the same set of parameters.
Using this semi-quantitative measurement, the
average areas of lung hyperproliferative lesions were 8.2,
50.2, 51.2, and 49.5% in C/EL858R bitransgenic mice
induced with Dox for 2, 4, 6, and 8 weeks, respectively
(Fig. 5B). In comparison, the average areas of lung
hyperproliferative lesions in Line-65 of C/Sdn/EL858R
(C/S65/EL858R) tritransgenic mice were 7.1, 26.8, 28.9,
and 31.3% after induction with Dox for 2, 4, 6, and 8
weeks, respectively. In the Line-669 of C/Sdn/EL858R
(C/S669/EL858R) tritransgenic mice, the average areas of
lung hyperproliferative lesions after the same time periods
of induction were 4.7, 21.4, 26.9, and 36.2%. Statistical
analysis showed that both lines of C/Sdn/EL858R
tritransgenic mice had significantly less areas of lung
hyperproliferative lesions than the C/EL858R bitransgenic
mice at 4, 6, and 8 weeks after Dox-induction (Fig. 5B).

At the 8-week time point, 3 out of 10 C/S65/EL858R
tritransgenic mice and 3 out of 10 C/S669/EL858R
tritransgenic mice had essentially normal lung histology or
minimal hyperproliferative lesions (Fig. 5A), whereas all
lungs from the 11 C/EL858R bitransgenic mice had >30%
areas of hyperproliferative lesions. Moreover, lung lesions
in the C/EL858R bitransgenic mice displayed a more
aggressive phenotype with the appearance of multifocal
compact masses of adenomas and adenocarcinomas (Fig.
5A).

Gab1 tyrosine phosphorylation and Shp2 binding
to Gab1 are inhibited in the C/Sdn/CL858R
tritransgenic mice
Shp2CSDA inhibited EGFRL858R-induced Erk1/2
activation in the lungs of transgenic mice (Fig. 4 and
Supplementary Fig. 3). Previous work has established that
Shp2 binding to Gab1 (or Gab2) is essential for Shp2 to
mediate Erk1/2 activation [2, 3, 5, 26].
Shp2 from lung of Dox-induced C/S669/EL858R
tritransgenic mice appeared to have less associated
tyrosine phosphorylated proteins and Gab1 than that
from Dox-fed C/EL858R bitransgenic mice (Fig. 6A). To
determine if Shp2CSDA bound to Gab1 or Gab2 in the
lungs of our tritransgenic mice, we immunoprecipitated the

Figure 6: Analysis of Gab1 tyrosine phosphorylation and association with Shp2 in transgenic mouse lung. A, lung tissue

lysates (4 mg/each) of C/EL858R (B) and C/S669/EL858R (T) mice induced with Dox diet for 6 weeks were immunoprecipitated with
anti-Shp2. Portions of immunoprecipitates (1/5, 1/5, 1/20) were analyzed by immunoblots with antibodies to phosphotyrosine (PY20),
Gab1, and Shp2, respectively. Ten μg of tissue lysates were also analyzed by immunoblot with an antibody to actin. B, Lung tissue
lysates from C/S669/EL858R mice induced with Dox diet for 4 weeks were immunoprecipitated with an anti-Flag antibody. One-tenth of
immunoprecipitates were analyzed by immunoblotting with an anti-phosphotyrosine antibody (PY20). The rest of immunoprecipitates were
separated on a SDS-polyacrylamide gel in the same experiment and gel slices were subjected to trypsin-digestion and protein identification
by LC/MS/MS. Bold letters indicate tyrosine phosphorylation residues have been identified on these proteins. Proteins in parentheses are
those that known to be tyrosine phosphorylated (based on www.phosphosite.org) that were detected in the indicated gel slices, but their
tyrosine-phosphorylated tryptic peptides were not detected in our experiment. C, Mouse lung tissue lysates from indicated genotypes fed
with Dox diet for 4 weeks were immunoprecipitated with the anti-Flag antibody and then immunoblotted with indicated antibodies. D,
Transgenic mice of indicated genotypes were fed with Dox diet for 4 weeks. Lung tissue lysates were analyzed by immunoblotting with
indicated antibodies (top panels). Gab1 was immunoprecipitated from these lung tissues and immunoblotted with antibodies to Shp2 or
Gab1 (lower panels).
www.impactjournals.com/oncotarget
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Flag-tagged Shp2CSDA from lung tissues of Dox-induced
C/S669/EL858R mice. Immunoprecipitates were separated
on gels and processed for immunoblotting analysis with
an anti-phosphotyrosine antibody or proteomic analysis
(Fig. 6B). Tyrosine phosphorylated Gab1 (on Y659) was
detected in one of the strong reactive bands to the antiphosphotyrosine antibody. Gab2 was not found in the
Shp2CSDA immunoprecipitates by the proteomic analysis,
possibly because Gab2 is not expressed in mouse lung
epithelial cells. Other tyrosine-phosphorylated proteins
detected were Shp2 (on Y62 and Y580 of the human
Shp2CSDA) and Mpzl1 (on Y263). No mouse-specific
Shp2 tryptic peptide was detected in the Flag-tagged
Shp2CSDA immunoprecipitates by the mass spectrometric
analysis (Supplementary Fig. 5). In a separate experiment,
we confirmed co-immunoprecipitation of Shp2CSDA and
Gab1 in lung tissues from Dox-induced tritransgenic mice
by immunoblotting the Shp2CSDA immunoprecipitates
with an anti-Gab1 antibody, although the amount of Gab1
protein co-immunoprecipitated with Shp2CSDA was low
(Fig. 6C).
We next compared Gab1 tyrosine phosphorylation
at the Shp2 binding site (pY627) and Gab1-bound Shp2
in lung tissues from the wildtype, C/EL858R, and C/
Sdn/CL858R mice Dox-induced for 4 weeks. Elevated
pGab1 (Y627) and Gab1-bound Shp2 were observed in
the lung tissue from C/EL858R bitransgenic mice (Fig.
6D). Tissues from both C/S65/EL858R and C/S669/
EL858R tritransgenic mice displayed markedly decreased
pGab1 and Gab1-bound Shp2 (Fig. 6D). These results
indicate that Shp2CSDA not only competed with the
endogenous Shp2 for Gab1 binding but also reduced Gab1
phosphorylation at the Shp2 binding site, thus preventing
binding and activation of the endogenous Shp2 by
EGFRL858R in the lungs of tritransgenic mice.

the marker of Shp2 activation in these studied. However,
it has reported that EGFR does not phosphorylate Shp2
C-terminal tyrosine residues well and the potential Y542
phosphorylation mediated docking function only plays a
peripheral, if any, role in EGFR signaling [29]. Moreover,
constitutive Erk1/2 activation by mutant EGFR could
result in feedback inhibition that may contribute to a
lower level of constitutive or transient peak pErk1/2. It is
possible that other genetic alternations in the few wildtype
EGFR cell lines also contribute to Erk1/2 activation in
these cells. In fact, the difference in Erk activation in
MEF cells transfected with wildtype and mutant EGFR
was small [27].
Gab1-Shp2 binding activates Shp2 [2]. Constitutive
Gab1-Shp2 binding in human lung adenocarcinoma cells
harboring mutant EGFR was observed in a previous study
[28] and in this study (Fig. 1). Moreover, constitutive
pErk1/2 was readily detectable in these cells that carry
mutant EGFR. Using Shp2 siRNAs, Dox-inducible
shRNAs, Shp2 binding defective Gab1 mutant, and
PTP-inactive Shp2 mutant, we have provided evidence
that inhibition of Gab1-Shp2 interaction and Shp2 PTP
activity suppress Erk1/2 activation in the HCC827
lung adenocarcinoma cells that harbor a mutant EGFR.
Although Shp2 knockdown and a Shp2 PTP inhibitor
suppress cell proliferation and pErk1/2, it is unlikely that
inhibition of Erk1/2 is the only mechanism that Shp2
mediates cell proliferation or tumorigenesis. Nevertheless,
pErk1/2 level provides a marker suitable for monitoring
Shp2 inhibition in many cases.
We found previously that the constitutively active
Shp2E76K mutant increased Gab1 tyrosine phosphorylation
in the lungs of transgenic mice and in cell lines via a
mechanism involving Src family kinases [17], suggesting
that the active Shp2 exerts a positive feedback loop to
regulate its binding to Gab1. Data in this study show that
the PTP-defective Shp2CSDA mutant suppresses Gab1
tyrosine phosphorylation and Src family kinases in the
lung of tritransgenic mice. This finding provides another
line of evidence to reinforce the notion that Shp2 controls
a positive feedback loop to regulate its own activity. In
the case of GOF active Shp2 mutants, this autoregulatory
loop is essential for Gab1/Gab2 phosphorylation necessary
for the oncogenic activity, because an active Shp2 PTP
needs to dock to Gab1/Gab2 to exert its function. Since the
endogenous mouse Shp2 in the lungs must dock to Gab1
in order to mediate mutant EGFR signaling, our finding
that Shp2CSDA suppresses Gab1 tyrosine phosphorylation
and Gab1-Shp2 binding provides a mechanistic insight
into how Shp2CSDA exerts a dominant negative effect
on the endogenous Shp2. Consistent with regulation of
SFKs by Shp2, our data show that active SFK levels were
decreased in tritransgenic mice expressing Shp2CSDA,
implicating SFKs in the Shp2 autoregulatory loop in these
mice, although this remains to be verified experimentally.
Our transgenic animal study represents a significant

DISCUSSION
It was previously unclear whether Shp2 is activated
by oncogenic EGFR mutants and whether inhibition of
the Shp2 PTP activity can suppress lung tumorigenesis in
vivo. In this study, we generated novel transgenic mice
containing a Dox-inducible PTP-defective Shp2CSDA.
We found that endogenous Shp2 is activated in the lung
tissues of transgenic mice in vivo by the EGFRL858R
mutant. Importantly, expression of the dominant-negative
Shp2CSDA mutant suppressed EGFRL858R-induced lung
adenocarcinoma in tritransgenic mice. These results
suggest that Shp2 contributes to the EGFR mutantinduced lung tumorigenesis and that inhibiting the PTP
activity of Shp2 can suppress EGFR mutant-induced lung
adenocarcinomas.
In human lung cancer cell lines harboring either
the wildtype or mutant EGFR, it was reported that Shp2
and Erk1/2 were less active in cells harboring mutant
EGFR [27, 28]. Shp2 Y542 phosphorylation was used as
www.impactjournals.com/oncotarget
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advance over previous subcutaneous tumor xenograft
experiments with breast and lung cancer cells [6, 7].
First, Shp2 knockdown in tumor cells depletes the
entire Shp2 protein. Besides the PTP activity, Shp2
contains SH2 domains and two Grb2-binding tyrosine
phosphorylation sites. When Shp2 is knocked down, all
three functional regions of Shp2 are lost. These include
not only the PTP activity but also the potential SH2
domain competition and Grb2-binding activity of Shp2
C-terminal phosphorylation sites. Thus, Shp2 knockdown
may not reflect the true phenotype when the Shp2 PTP
activity is inhibited by a drug because the small molecular
PTP inhibitor only suppresses Shp2 PTP activity while
leaving the SH2 domains and tyrosine phosphorylation
sites intact. By analogy, a Shp2 knockout mouse model
would have the same limitation. In contrast, Shp2CSDA
only affects the PTP activity and thus is a better model of
Shp2 PTP inhibition. Second, previous studies measured
subcutaneous tumor xenografts not grown in their
natural environments in immunocompetent hosts. Our
study is the first evaluation of Shp2 inhibition in a PTK
oncogene-driven tumor development model in genetically
engineered animals.
A major mechanism of drug resistance to EGFR
TKIs in lung adenocarcinoma is reactivation of the mutant
EGFR PTK activity. Moreover, de novo resistance to
EGFR TKIs has also been associated with constitutively
active EGFR PTK activity. Under these circumstances, our
data suggest that the Gab1-Shp2 pathway is activated in
these EGFR inhibitor-resistant lung adenocarcinoma cells
and promotes tumor growth. Increasing evidence suggests
that PTK-PTP cooperate to promote human cancer
development and PTP inhibitors are being developed as
potential anti-cancer drugs. Our finding that the PTPdefective Shp2CSDA suppresses EGFRL858R-induced lung
adenocarcinoma in transgenic mice suggests that Shp2
PTP is a potential target for therapeutic development in
EGFR-driven lung adenocarcinoma. Consistent with
previous studies in cell cultures of lung cancer cells,
we observed elevated pAkt and pStat3 in the lungs of
transgenic mice when EGFRL858R was expressed. While
inhibition of Shp2 had little effect on pAkt and pStat3
in our mouse model, it is possible but remains to be
tested that combining Shp2 inhibition with blockage of
the phosphoinoside-3-kinase-Akt pathway and/or Stat3
signaling may be a more effective therapy for EGFR
mutant-associated NSCLC that develop resistance to the
first-line EGFR PTK inhibitor therapy.

www.impactjournals.com/oncotarget

Reagents
On-target Smart pool Shp2-specific and nonsilencing control siRNAs were from Dharmacon. Shp2
shRNAs were described [6]. Gab1FF, Shp2CSDA, and
HA-Erk2 plasmids used in transfected experiments in cell
cultures have been described [2, 3, 5]. Erlotinib was from
LC Chemicals. WZ4002 was from Selleck. SPI-112Me
was synthesized as described [11]. Antibodies to Shp2,
Erk1/2, phospho-Erk1/2 (pErk1/2, T202/Y204), Gab1,
Akt, c-Myc, and β-actin were obtained from Santa Cruz
Biotechnology. Antibodies to Flag (rabbit), phospho-Gab1
(pGab1, Y627), phospho-Akt (pAkt, S473), and phosphoSrc (pSrc, Y416) were from Cell Signaling Technology.
Src antibody was from Calbiochem. The anti-Flag M2
monoclonal antibody was from Sigma.

Cell cultures, transfection, and cell proliferation
assay
Cell lines have been maintained in a central
repository at the Moffitt Cancer Center since 2008. All cell
lines in the Moffitt repository had been authenticated by
STR analysis (ACTG Inc, Wheeling, IL) as of September
2010, and all cells had been routinely tested and were
negative for mycoplasma (PlasmoTest, InvivoGen, San
Diego, CA). HCC827 and H1975 lung carcinoma cells
were cultured in RPMI1640 plus 10% fetal bovine serum
(FBS) at 37°C in 5% CO2. To examine the effect of siRNA
on cell proliferation, HCC827 and H1975 cells were plated
in 96-well plates (2,000 cells/well) in RPMI1640/10%FBS
for 24 h. Cells were transfected with 25 nM PTPN11
on-target smart pool siRNAs or non-silencing control
siRNA using Lipofectamine 2000 (Life Technologies)
for 4 h. After 6 days, viable cells were measured using
CellTiter-Glo reagent (Promega). For immunoblotting
analysis, HCC827 and H1975 cells were plated in 12well plates (20,000 cells/well) in RPMI1640/10%FBS
for 24 h before transfection with 25 nM siRNAs for 6 h
as above. Cell lysates were prepared and analyzed 3 days
after transfection. For SPI-112Me treatment, HCC827
and H1975 cells were plated in 96-well plates (1,000
cells/well) in RPMI1640/10%FBS for 24 h and then
incubated with SPI-112Me or solvent control for 6 days
before analyzing relative cell numbers using CellTiter-Glo
reagent.
Transfection of HCC827 cells with Gab1 and
Shp2 mutants were performed in 6-cm plates containing
overnight cultures of 7x105 cells/plate. Each plate of
cells were transfected with 2 μg HA-Erk2 plasmid plus
2 μg of either pCDNA3.1 vector, pCDNA3.1-Gab1FF, or
pCDNA3.1-Shp2CSDA using lipofectamine 2000. Forty6199
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eight h after transfection, cells were serum-started for
18 h and stimulated with EGF (2 ng/ml, 10min) or left
untreated. HA-Erk2 was immunoprecipitated and analyzed
by immunoblotting as described [5].

CCSP-rtTA transgenic mice were genotyped as described
[25]. The tetO-EGFRL858R transgenic mice were genotyped
as described [19].
Animals were maintained in specific pathogenfree housing conditions. To activate the transactivating
function of the rtTA protein, mice were fed with rodent
chow containing 200 mg/kg doxycycline (Dox diet,
Bio-Serv). Animal studies and care were approved by
the Institutional Animal Care and Use Committee of the
University of South Florida and followed institutional and
national guidelines.

Immunoblotting and immunoprecipitation
Frozen tissues and cells were lysed for 1 h at 4 °C
using lysis buffer (50 mM Tris-HCl, pH 7.5, 150 mM
NaCl, 1 mM EDTA, 1 mM EGTA, 25 mM NaF, 5 mM
Na4P2O7, 1 mM dithiothreitol, 1 mM Na3VO4, 100 µg/ml
of phenylmethylsulfonyl fluoride, 2 µg/ml leupeptin, 2
µg/ml aprotinin, and 1% Triton X-100). Equal amounts
of proteins from cleared lysates were separated by 10%
SDS-polyacrylamide gels and transferred to nitrocellulose
filters for immunoblotting. Flag-tagged Shp2CSDA
was immunoprecipitated from cleared tissue lysate
supernatants by using the anti-Flag M2 antibody. Gab1
was immunoprecipitated using Gab1 mouse antibody.
Immunoblotting was performed as described previously
[6, 30-32].

RT-PCR analysis of Shp2CSDA mRNA
RNA was extracted from frozen tissues using
Trizol reagent (Life Technologies). Samples were
treated with DNase I to avoid DNA contamination
and RT-PCR was performed using the SuperScript
One-Step RT-PCR Platinum Taq system (Life
Technologies) with the following primers: SHP2F1:
5’-GGTTGGACAAGGGAATACGG-3’ and SHP2R2:
5’-AGGGCTCTGATCTCCACTCG-3’. The protocol for
a 50 µl RT-PCR reaction was: 30 min cDNA synthesis at
55 oC, 4 min denaturation at 94 oC then 35 cycles of 94 oC
for 30 sec, 57 oC for 30 sec, then 72 oC for 30 sec with a
final extension step of 72oC for 4 min which yields a 462bp fragment.

Transgenic mice
A Cre recombinase-mediated cassette exchange
(RMCE)-capable plasmid L3/L2-tetO (Fig. 3A) was
constructed [17]. cDNA encoding Flag-tagged, C459S/
D425A mutations of human Shp2 (Shp2CSDA) [5] was
then subcloned into the EcoRV site between the tetO
and polyA sequences in L3/L2-tetO to create the L3/L2tetO-Shp2CSDA plasmid (Fig. 3A). To generate tetOShp2CSDA transgenic mice, the 5.8 kb BssHII fragment
of L3/L2-tetO-Shp2CSDA transgene was isolated
by agarose gel electrophoresis followed by EluTrap
electroelution and EluTip purification (Whatman).
Ethanol precipitated DNA was resuspended in sterile
microinjection buffer (10 mM Tris-HCl, 0.1 mM EDTA,
pH 7.5) and microinjected at 3 ng/µl into 0.5 dpc fertilized
FVB/N zygotes. Zygotes were surgically implanted into
the oviducts of 0.5 dpc pseudopregnant CD-1 females for
development. Offspring were tail biopsied at weaning and
genomic DNA screened by PCR to identify transgenic
lines. Genotyping of tetO-Shp2CSDA transgenic mice
was performed using the GoTaq® Hot Start Green Master
Mix (Promega) and the following primers: SHP2T1, 5’AGACGCCATCCACGCTGTTTTGAC-3’ and SHP2T2,
5’-TCTCTTTTAATTGCCCGTGATGTT-3’. The protocol
for a 25 µl PCR reaction was: 4 min denaturation at 94 oC,
35 cycles of 94 oC for 30 sec, 57oC for 30 sec, 72 oC for 30
sec with a final extension step of 72 oC for 4 min, which
yields a 450-bp PCR fragment.
CCSP-rtTA transgenic mice (on inbred FVB/N
background) [25] were provided by Dr. Jeffrey A. Whitsett.
TetO-EGFRL858R transgenic mice (in B6;CBA) [19] were
obtained from the NCI-Frederick Mouse Repository. The
www.impactjournals.com/oncotarget

Histological examination
After euthanasia, mouse lungs were flushed twice
with 10 ml PBS, insufflated with 10% buffered formalin,
and placed with the frontal side of the lungs oriented
towards the bottom of embedding cassettes. After
overnight fixation with formalin at room temperature,
paraffin blocks were prepared using standard procedures
by the Tissue Core at the Moffitt Cancer Center. Three
sections (4 µm thick) were cut 25 µm apart. These
tissue sections were stained with hematoxylin and eosin
(H&E) for histological examination and analysis of
hyperproliferative lesions.
After histological examination by two pathologists,
H&E stain slides were scanned using a ScanScope XT
(Aperio) with a 20x/0.8NA objective lens at a rate of 5
minutes per slide via Basler tri-linear-array to acquire
whole slide images. Genie® v1 histology pattern
recognition software (Aperio) was used to segment
hyperproliferative lesions from other lung tissue areas
and background. This was accomplished using the Aperio
Nuclear® v9.1 algorithm with a training set of 400
iterations and pathologist quality control. The optimized
thresholds were: Averaging radius = 1 µm; Segmentation
Type = 2 Cytoplasmic Rejection; Threshold Type = 1Edge Threshold with weighted Trimming; Min/ Max Nuc
Size = 25 µm2/1000000 μm2/; RGB stain = 0/ 0.64307/
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0.31756; Positive RGB OD = 0.244583/ 0.509334/
0.825081. The resultant hyperproliferative areas were
calculated as a percentage of lung tissue areas.

bisphosphoryl tyrosine-based activation motif (BTAM)
conferring binding and activation of SHP2. J Biol Chem.
2001; 276(26):24380-24387.

Proteomic analysis
Protein identification by mass spectrometry was
performed by the Proteomics Core of the Moffitt Cancer
Center using standard procedures. Briefly, gel slices were
treated with TCEP and iodoacetamide to reduce and
alkylate proteins. After in-gel trypsin digestion, peptides
were extracted and concentrated. A nanoflow ultra high
performance liquid chromatograph (RSLC, Dionex,
Sunnyvale, CA) coupled to an electrospray ion trap mass
spectrometer (LTQ-Orbitrap, Thermo, San Jose, CA) was
used for tandem mass spectrometry peptide sequencing
analysis. Five tandem mass spectra were collected in a
data-dependent manner following each survey scan. The
MS scans were performed in Orbitrap to obtain accurate
peptide mass measurement and the MS/MS scans were
performed in linear ion trap using 60 second exclusion for
previously sampled peptide peaks. Mascot and Sequest
searches were performed against the Swiss-Prot mouse
and human databases. Dynamic modifications included
carbamidomethylation (Cys), oxidation (Met), and
phosphorylation (Ser/Thr/Tyr). Both Mascot and Sequest
search results were compiled in Scaffold.

Statistical analysis
Statistical analysis was performed using unpaired
t test with Welch’s correction, without assuming equal
SDs. A difference in means with p < 0.05 was considered
statistically significant.
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